Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Frequently asked questions
What sector does Cardiol Therapeutics Inc Class A (CRDL) operate in?
Cardiol Therapeutics Inc Class A belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Cardiol Therapeutics Inc Class A (CRDL) current stock price?
As of the latest data, Cardiol Therapeutics Inc Class A stock price is CA$1.60, with a previous close of CA$1.59. Cardiol Therapeutics Inc Class A gained CA$0.01 in the last trading session, representing a 0.63% increase.
What is Cardiol Therapeutics Inc Class A (CRDL) current market capitalization?
Cardiol Therapeutics Inc Class A market cap is approximately 193.06 million.
What is Cardiol Therapeutics Inc Class A (CRDL) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.34, and the forward EPS is -CA$0.33.
What is Cardiol Therapeutics Inc Class A (CRDL) EBITDA?
Cardiol Therapeutics Inc Class A EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.93 million.
Does Cardiol Therapeutics Inc Class A (CRDL) pay dividends?
No. Cardiol Therapeutics Inc Class A does not pay a dividend.
When is Cardiol Therapeutics Inc Class A (CRDL) next earnings report?
Cardiol Therapeutics Inc Class A is expected to release its next earnings report on September 30, 2026.
What is Cardiol Therapeutics Inc Class A (CRDL) beta (volatility) score?
Cardiol Therapeutics Inc Class A has a beta of 0.606, indicating lower volatility than the overall market.
